Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets in light of data and competition

Amgen is bowing out (PDF) of the congested BCMA race. With a who’s who of drug developers going after the multiple myeloma target, the big biotech has decided to stop work on its bispecific contender as part of a cull that also saw it pick between its two PSMA prospects.